Please enable JavaScript to continue using this application.

Compare $LCTX vs $UPB | Chartloom

Compare

$LCTX vs $UPB

Lineage Cell Therapeutics Inc · Upstream Bio Inc

LCTX

Lineage Cell Therapeutics Inc

UPB

Upstream Bio Inc

Compare $LCTX vs $UPB

Comparing Lineage Cell Therapeutics Inc and Upstream Bio Inc

LCTXLineage Cell Therapeutics Inc

UPBUpstream Bio Inc

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

UPBUpstream Bio Inc

Market cap

$256M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

168.72x

Rev growth (TTM)

16.0%

YTD performance

-82.6%

52W performance

-75.2%

FCF yield

-53.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LCTX

UPB

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

UPB

Upstream Bio Inc

Market Cap

LCTX$248M

UPB$256M

Enterprise Value

LCTX$210M

UPB$176M

Price

LCTX$0.99

UPB$4.70

P/E Ratio

LCTXN/A

UPBN/A

P/S Ratio

LCTX18.94x

UPB80.99x

EV/Sales

LCTX16.09x

UPB55.85x

EV/EBITDA

LCTX0.00x

UPB0.00x

P/B Ratio

LCTX3.86x

UPB1.02x

P/FCF Ratio

LCTXN/A

UPBN/A

EV/FCF

LCTX-8.48x

UPB-1.29x

PEG Ratio

LCTXN/A

UPBN/A

Forward P/E (NTM)

LCTXN/A

UPBN/A

Forward P/S (NTM)

LCTX28.49x

UPB168.72x

Revenue (TTM)

LCTX$13M

UPB$3M

Revenue Growth (YoY)

LCTX-37.1%

UPB16.0%

Forward Rev Growth

LCTX-16.6%

UPB-48.7%

Gross Margin (TTM)

LCTX94.1%

UPB0.0%

Operating Margin (TTM)

LCTX0.0%

UPB0.0%

EBITDA Margin (TTM)

LCTX-199.6%

UPB-5376.3%

Net Margin (TTM)

LCTX-246.6%

UPB-4955.7%

FCF Margin (TTM)

LCTX-189.7%

UPB-4321.2%

Net Income (TTM)

LCTX$-32M

UPB$-157M

FCF (TTM)

LCTX$-25M

UPB$-136M

EPS (TTM)

LCTX-$0.13

UPB-$2.87

ROE (TTM)

LCTX-7114.0%

UPB-4840.0%

ROA (TTM)

LCTX-3087.0%

UPB-4657.0%

ROIC (TTM)

LCTX-7104.0%

UPB-4840.0%

Cash

LCTX$37M

UPB$79M

Debt

LCTX$48K

UPB$0

Net Cash/Debt

LCTX$37M

UPB$79M

Current Ratio (TTM)

LCTX6.61x

UPB27.99x

Quick Ratio (TTM)

LCTX6.44x

UPB27.84x

Debt/Equity (TTM)

LCTX0.00x

UPB0.00x

Debt/Assets (TTM)

LCTX0.0%

UPB0.0%

Interest Coverage (TTM)

LCTXN/A

UPBN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

UPB0.00x

Beta

LCTX1.67

UPB2.30

52W Performance

LCTX-42.5%

UPB-75.2%

YTD Performance

LCTX-39.4%

UPB-82.6%

% from 52W High

LCTX-52.4%

UPB-86.0%

% from 52W Low

LCTX12.7%

UPB7.7%

Asset Turnover (TTM)

LCTX0.07x

UPB0.01x

FCF Yield (TTM)

LCTX-10.0%

UPB-53.4%

Earnings Yield (TTM)

LCTX-13.0%

UPB-61.2%

Dividend Yield (TTM)

LCTXN/A

UPBN/A

Rule of 40

LCTX-226.8

UPB-4,305.2

EV/GP/RG

LCTXN/A

UPBN/A

Ticker research

View LCTX research View UPB research

Metric	LCTX Lineage Cell Therapeutics Inc	UPB Upstream Bio Inc
Market & Valuation
Market Cap	$248M	$256M
Enterprise Value	$210M	$176M
Price	$0.99	$4.70
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	80.99x
EV/Sales	16.09x	55.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-1.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	168.72x
Revenue & Growth
Revenue (TTM)	$13M	$3M
Revenue Growth (YoY)	-37.1%	16.0%
Forward Rev Growth	-16.6%	-48.7%
Profitability
Gross Margin (TTM)	94.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-5376.3%
Net Margin (TTM)	-246.6%	-4955.7%
FCF Margin (TTM)	-189.7%	-4321.2%
Net Income (TTM)	$-32M	$-157M
FCF (TTM)	$-25M	$-136M
EPS (TTM)	-$0.13	-$2.87
ROE (TTM)	-7114.0%	-4840.0%
ROA (TTM)	-3087.0%	-4657.0%
ROIC (TTM)	-7104.0%	-4840.0%
Financial Health
Cash	$37M	$79M
Debt	$48K	$0
Net Cash/Debt	$37M	$79M
Current Ratio (TTM)	6.61x	27.99x
Quick Ratio (TTM)	6.44x	27.84x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	2.30
52W Performance	-42.5%	-75.2%
YTD Performance	-39.4%	-82.6%
% from 52W High	-52.4%	-86.0%
% from 52W Low	12.7%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.01x
FCF Yield (TTM)	-10.0%	-53.4%
Earnings Yield (TTM)	-13.0%	-61.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-4,305.2
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View UPB research

Valuation

P/S Ratio

LCTX

18.94x

UPB

80.99x

EV/FCF

LCTX

-8.48x

UPB

-1.29x

Growth & revenue

Revenue Growth TTM

UPB

16.0%

LCTX

-37.1%

Forward Revenue Growth

LCTX

-16.6%

UPB

-48.7%

Profitability & performance

Gross Margin

LCTX

94.1%

UPB

0.0%

ROE

UPB

-4840.0%

LCTX

-7114.0%

FCF Yield %

LCTX

-10.0%

UPB

-53.4%

52-Week Performance

LCTX

-42.5%

UPB

-75.2%

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

UPB

Upstream Bio Inc

Market Cap

LCTX$248M

UPB$256M

Enterprise Value

LCTX$210M

UPB$176M

Price

LCTX$0.99

UPB$4.70

P/E Ratio

LCTXN/A

UPBN/A

P/S Ratio

LCTX18.94x

UPB80.99x

EV/Sales

LCTX16.09x

UPB55.85x

EV/EBITDA

LCTX0.00x

UPB0.00x

P/B Ratio

LCTX3.86x

UPB1.02x

P/FCF Ratio

LCTXN/A

UPBN/A

EV/FCF

LCTX-8.48x

UPB-1.29x

PEG Ratio

LCTXN/A

UPBN/A

Forward P/E (NTM)

LCTXN/A

UPBN/A

Forward P/S (NTM)

LCTX28.49x

UPB168.72x

Revenue (TTM)

LCTX$13M

UPB$3M

Revenue Growth (YoY)

LCTX-37.1%

UPB16.0%

Forward Rev Growth

LCTX-16.6%

UPB-48.7%

Gross Margin (TTM)

LCTX94.1%

UPB0.0%

Operating Margin (TTM)

LCTX0.0%

UPB0.0%

EBITDA Margin (TTM)

LCTX-199.6%

UPB-5376.3%

Net Margin (TTM)

LCTX-246.6%

UPB-4955.7%

FCF Margin (TTM)

LCTX-189.7%

UPB-4321.2%

Net Income (TTM)

LCTX$-32M

UPB$-157M

FCF (TTM)

LCTX$-25M

UPB$-136M

EPS (TTM)

LCTX-$0.13

UPB-$2.87

ROE (TTM)

LCTX-7114.0%

UPB-4840.0%

ROA (TTM)

LCTX-3087.0%

UPB-4657.0%

ROIC (TTM)

LCTX-7104.0%

UPB-4840.0%

Cash

LCTX$37M

UPB$79M

Debt

LCTX$48K

UPB$0

Net Cash/Debt

LCTX$37M

UPB$79M

Current Ratio (TTM)

LCTX6.61x

UPB27.99x

Quick Ratio (TTM)

LCTX6.44x

UPB27.84x

Debt/Equity (TTM)

LCTX0.00x

UPB0.00x

Debt/Assets (TTM)

LCTX0.0%

UPB0.0%

Interest Coverage (TTM)

LCTXN/A

UPBN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

UPB0.00x

Beta

LCTX1.67

UPB2.30

52W Performance

LCTX-42.5%

UPB-75.2%

YTD Performance

LCTX-39.4%

UPB-82.6%

% from 52W High

LCTX-52.4%

UPB-86.0%

% from 52W Low

LCTX12.7%

UPB7.7%

Asset Turnover (TTM)

LCTX0.07x

UPB0.01x

FCF Yield (TTM)

LCTX-10.0%

UPB-53.4%

Earnings Yield (TTM)

LCTX-13.0%

UPB-61.2%

Dividend Yield (TTM)

LCTXN/A

UPBN/A

Rule of 40

LCTX-226.8

UPB-4,305.2

EV/GP/RG

LCTXN/A

UPBN/A

Ticker research

View LCTX research View UPB research

Metric	LCTX Lineage Cell Therapeutics Inc	UPB Upstream Bio Inc
Market & Valuation
Market Cap	$248M	$256M
Enterprise Value	$210M	$176M
Price	$0.99	$4.70
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	80.99x
EV/Sales	16.09x	55.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-1.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	168.72x
Revenue & Growth
Revenue (TTM)	$13M	$3M
Revenue Growth (YoY)	-37.1%	16.0%
Forward Rev Growth	-16.6%	-48.7%
Profitability
Gross Margin (TTM)	94.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-5376.3%
Net Margin (TTM)	-246.6%	-4955.7%
FCF Margin (TTM)	-189.7%	-4321.2%
Net Income (TTM)	$-32M	$-157M
FCF (TTM)	$-25M	$-136M
EPS (TTM)	-$0.13	-$2.87
ROE (TTM)	-7114.0%	-4840.0%
ROA (TTM)	-3087.0%	-4657.0%
ROIC (TTM)	-7104.0%	-4840.0%
Financial Health
Cash	$37M	$79M
Debt	$48K	$0
Net Cash/Debt	$37M	$79M
Current Ratio (TTM)	6.61x	27.99x
Quick Ratio (TTM)	6.44x	27.84x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	2.30
52W Performance	-42.5%	-75.2%
YTD Performance	-39.4%	-82.6%
% from 52W High	-52.4%	-86.0%
% from 52W Low	12.7%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.01x
FCF Yield (TTM)	-10.0%	-53.4%
Earnings Yield (TTM)	-13.0%	-61.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-4,305.2
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View UPB research